Gurnee, IL, August 3, 2009
Essential CRO and Ecron Acunova have announced the formation of a global strategic alliance. The alliance network is established through a combination of Essential CRO’s presence in Gurnee, Illinois with Ecron Acunova, based in Bangalore, India with its U.S. office in Princeton, NJ and an established presence, headquartered in Frankfurt, Germany, across 14 countries in Europe.
While Essential and Ecron Acunova have been partners for several years, the magnitude of project size and positive feedback from sposors on the combined team execution have influenced the establishment of this alliance. The alliance has passed several international clients QA audits over the past two years reinforcing the quality of execution. In the past six months the alliance has won global projects in the eight figure range in over 14 countries from leading mid-sized biotech and large pharma sponsors.
About Essential
Essential provides CRO and patient recruitment services. The organization’s two main service offerings of CRO and patient recruitment services are independent, yet fully integrated. Visit www.essentialgroupinc.com for more information.
About Ecron Acunova
Ecron Acunova is headquartered in Bangalore, India with European HQ in Frankfurt, Germany and US HQ in Princeton, NJ. Ecron Acunova provides services for Phase I–IV clinical research, including Clinical Trial Management, Clinical Data Management, PK/PD services and Central Lab with its research centers in Germany and India. Ecron Acunova provides clinical development services to the pharmaceutical, biotechnology, nutritional, device and medical diagnostics industries. Visit www.ecronacunova.com for more information.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.